Search results for " severity of illness"

showing 10 items of 104 documents

Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register

2018

Abstract Background Frailty is a state of increased vulnerability to stressors, associated to poor health outcomes. The aim of this study was to design and introduce a Frailty Index (FI; according to the age-related accumulation of deficit model) in a large cohort of hospitalized older persons, in order to benefit from its capacity to comprehensively weight the risk profile of the individual. Methods Patients aged 65 and older enrolled in the REPOSI register from 2010 to 2016 were considered in the present analyses. Variables recorded at the hospital admission (including socio-demographic, physical, cognitive, functional and clinical factors) were used to compute the FI. The prognostic impa…

GerontologyMaleMultivariate analysisFrailty; Internal medicine and geriatric wards; Multimorbidity; Physical and cognitive impairment; Internal MedicinePhysical and cognitive impairmentPsychological interventionPredictive Value of TestSeverity of Illness Index0302 clinical medicineInternal medicine and geriatric wardsInterquartile rangeFrailty Internal medicine and geriatric wards Multimorbidity Physical and cognitive impairment80 and overMedicine030212 general & internal medicineProspective StudiesHospital MortalityProspective cohort studyMultivariate AnalysiAged 80 and overFrailtyPrognosisFrailty; Internal medicine and geriatric wards; Multimorbidity; Physical and cognitive impairment; Aged; Aged 80 and over; Female; Frailty; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Multimorbidity; Multivariate Analysis; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Survival Analysis; Frail Elderly; Hospital Mortality; Severity of Illness IndexHospitalizationItalyPredictive value of testsRegression AnalysisFemaleSurvival AnalysiCohort studyHumanPrognosiFrail ElderlyFrailty; Internal medicine and geriatric wards; Multimorbidity; Physical and cognitive impairment; Aged; Aged 80 and over; Female; Frailty; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Multimorbidity; Multivariate Analysis; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Survival Analysis; Frail Elderly; Hospital Mortality; Severity of Illness Index; Internal MedicineSocio-culturaleRegression Analysi03 medical and health sciencesPredictive Value of TestsSeverity of illnessInternal MedicineHumansGeriatric AssessmentSurvival analysisAgedbusiness.industryMultimorbiditySurvival AnalysisInternal medicine and geriatric wardProspective StudieMultivariate Analysisbusiness030217 neurology & neurosurgery
researchProduct

Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational qual…

2006

OBJECTIVES: To compare health-related quality of life (HRQL) and to identify clinical determinants for poor HRQL of patients with juvenile idiopathic arthritis (JIA) coming from three geographic areas.METHODS: The HRQL was assessed through the Child Health Questionnaire (CHQ). A total of 30 countries were included grouped in three geographic areas: 16 countries in Western Europe; 10 in Eastern Europe; and four in Latin America. Potential determinants of poor HRQL included demographic data, physician's and parent's global assessments, measures of joint inflammation, disability as measured by Childhood Health Assessment Questionnaire (CHAQ) and erythrocyte sedimentation rate. Poor HRQL was de…

GerontologyQuality of lifeCross-Cultural ComparisonMalemedicine.medical_specialtyDisability; Juvenile idiopathic arthritis; Pain; Quality of life; Adolescent; Arthritis Juvenile; Child; Cross-Cultural Comparison; Cross-Sectional Studies; Disability Evaluation; Europe; Europe Eastern; Female; Humans; Latin America; Male; Pain Measurement; Severity of Illness Index; Quality of LifeAdolescentCross-sectional studyPainJuvenileEasternSeverity of Illness IndexDisability EvaluationQuality of life (healthcare)RheumatologySeverity of illnessmedicineGlobal healthHumansPharmacology (medical)Europe EasternChildPain MeasurementDisabilitybusiness.industryArthritisJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenilehumanitiesEuropeCross-Sectional StudiesLatin AmericaHealth assessmentPhysical therapyFemalebusinessPsychosocialJuvenile rheumatoid arthritisCohort study
researchProduct

Sepsis at ICU admission does not decrease 30-day survival in very old patients : a post-hoc analysis of the VIP1 multinational cohort study

2020

AbstractBackgroundThe number of intensive care patients aged ≥ 80 years (Very old Intensive Care Patients; VIPs) is growing. VIPs have high mortality and morbidity and the benefits of ICU admission are frequently questioned. Sepsis incidence has risen in recent years and identification of outcomes is of considerable public importance. We aimed to determine whether VIPs admitted for sepsis had different outcomes than those admitted for other acute reasons and identify potential prognostic factors for 30-day survival.ResultsThis prospective study included VIPs with Sequential Organ Failure Assessment (SOFA) scores ≥ 2 acutely admitted to 307 ICUs in 21 European countries. Of 3869 acutely admi…

INTENSIVE-CARE-UNITSurvivalHSJ UCICritical Care and Intensive Care Medicinesurvival analysislaw.inventionsepsisSeverity of illne0302 clinical medicineLONG-TERM OUTCOMESoverlevingsanalyselawMedicine and Health SciencesEPIDEMIOLOGYIntensive care; Mortality; Outcome; Sepsis; Severity of illness; Survival; Very old030212 general & internal medicineProspective cohort studyELDERLY-PATIENTSOutcomeddc:617PATIENTS AGED 80lcsh:Medical emergencies. Critical care. Intensive care. First aidVery OldIntensive care unitSOFA scoremedicine.symptomCRITICALLY-ILL PATIENTSWITHDRAWALhormones hormone substitutes and hormone antagonistsmedicine.medical_specialtySepsiVery oldelderly patientsSeverity of illnessNOSepsis03 medical and health sciencessterfteSepsisInternal medicineIntensive careSeverity of illnessmedicineMortalityFRAILTYbusiness.industrySeptic shockResearchSEPTIC SHOCKOrgan dysfunctionIntensive Care030208 emergency & critical care medicinelcsh:RC86-88.9oudere patiëntenmedicine.diseaseIntensive carebusiness
researchProduct

Italian multicentric survey on laparoscopic spleen surgery in the pediatric population.

2007

Abstract Background: Some technical aspects of laparoscopic spleen surgery still are debated, although efforts have been made to standardize them. The position of the patient, the approach to the spleen, vessel identification and division, and spleen extraction can vary from center to center. Methods: This retrospective muticentric study led by the Societa` Italiana di Videochirurgia Infantile (SIVI) examined indications, surgical details, and complications of laparoscopic spleen surgery in the pediatric population during a 5-year period. Results: The study period from January 1999 to December 2003 (5 years) involved nine centers and included 85 patients with a mean age of 10 years (range, …

Laparoscopic surgeryMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentSplenectomySpleenAdolescent Age Distribution Child Child; Preschool Data Collection Female Hematologic Diseases; complications/diagnosis Humans Incidence Intraoperative Complications; diagnosis/epidemiology Italy Laparoscopy; adverse effects/methods Male Pediatrics; methods Postoperative Complications; diagnosis/epidemiology Prognosis Retrospective Studies Risk Assessment Severity of Illness Index Sex Distribution Splenectomy; adverse effects/methods Splenic Diseases; diagnosis/etiology/surgery Survival AnalysisPediatricsRisk AssessmentSeverity of Illness IndexmethodsAge DistributionPostoperative ComplicationsmedicineHumansSex DistributionLaparoscopyChildPreschoolIntraoperative ComplicationsRetrospective StudiesSplenic Diseasesadverse effects/methodsmedicine.diagnostic_testdiagnosis/epidemiologybusiness.industryData CollectionIncidenceComplications — Fenestration — Laparoscopic splenectomy — Multicentric survey — Spleen —technical detailscomplications/diagnosismedicine.diseasePrognosisdiagnosis/etiology/surgeryHematologic DiseasesSurvival AnalysisEndoscopySurgerymedicine.anatomical_structureItalyChild PreschoolSplenectomySurgeryFemaleLaparoscopySplenic diseasebusinessComplicationAbdominal surgery
researchProduct

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

2016

Background & Aims Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver damage and is characterized by steatosis. Genetic factors increase risk for progressive NAFLD. A genome-wide association study showed that the rs641738 C>T variant in the locus that contains the membrane bound O-acyltransferase domain-containing 7 gene (MBOAT7, also called LPIAT1) and transmembrane channel-like 4 gene (TMC4) increased the risk for cirrhosis in alcohol abusers. We investigated whether the MBOAT7-TMC4 is a susceptibility locus for the development and progression of NAFLD. Methods We genotyped rs641738 in DNA collected from 3854 participants from the Dallas Heart Study (a multi-ethnic…

Liver CirrhosisMale0301 basic medicineCirrhosisBiopsyProton Magnetic Resonance SpectroscopyPhosphatidylinositolsTriglycerideSeverity of Illness IndexGastroenterologyLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseMembrane Proteineducation.field_of_studyArachidonic Acidmedicine.diagnostic_testNASHGastroenterologyTexasEuropePhenotypeLiverLiver biopsyFemale030211 gastroenterology & hepatologyTexaCase-Control StudiePhosphatidylinositolHumanmedicine.medical_specialtyAcyltransferaseLiver CirrhosiEuropean Continental Ancestry GroupPopulationTM6SF2White PeopleArticle03 medical and health sciencesArachidonic Acid; NASH; PNPLA3; TM6SF2; Acetyltransferases; Acyltransferases; Biopsy; Case-Control Studies; Cross-Sectional Studies; Europe; European Continental Ancestry Group; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Liver; Liver Cirrhosis; Male; Membrane Proteins; Non-alcoholic Fatty Liver Disease; Phenotype; Phosphatidylinositols; Proton Magnetic Resonance Spectroscopy; Risk Factors; Severity of Illness Index; Texas; Triglycerides; Polymorphism GeneticGeneticAcetyltransferasesInternal medicineAcetyltransferasemedicineHumansGenetic Predisposition to DiseasePolymorphismeducationPNPLA3TriglyceridesCross-Sectional StudiePolymorphism GeneticHepatologybusiness.industryRisk FactorCase-control studyMembrane Proteinsmedicine.diseaseCross-Sectional Studies030104 developmental biologyEndocrinologyCase-Control StudiesSteatosisbusinessAcyltransferasesGenome-Wide Association StudyTM6SF2Gastroenterology
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct

[Postural balance following stroke: towards a disadvantage of the right brain-damaged hemisphere].

1999

International audience; In the light of studies published in the last ten years, we have suspected a differential influence of the sides of hemispheric cerebral lesions on posture and balance. A study was aimed at verifying this hypothesis, the method of which being original because many possible confounding factors such as age, sex as well as topography and size of the brain lesion have been taken into account in the statistical analysis. Inclusion criteria were: right-handed patients, first stroke, no previous disease which might have affected balance. Their postural abilities (ranging from 0 to 36) were assessed 90 +/- 3 days after stroke onset on a clinical scale. This clinical assessme…

MESH : MaleMESH : HumansMESH : AgedMESH : PostureMESH : Visual Fields[ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH : Vision DisordersMESH : BrainMESH : Postural BalanceMESH : Brain IschemiaMESH : Severity of Illness IndexMESH : FemaleMESH : Middle AgedMESH : Aged 80 and overMESH : Functional Laterality[SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences
researchProduct

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clini…

2009

Objective To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA). Methods Thirty-six rheumatologists stated their preferences for RA treatment after inadequate response with MTX therapy (optimal dose at least 6 months). From the initial scenario, we derived 54 vignettes varying by rheumatoid factor or anti–cyclic citrullinated peptide antibody presence, swollen joint count, Disease Activity Score in 28 joints, and structural damage. Respondents stated their preference among 5 therapeutic options: MTX continuation, switch to another conventional …

MESH: Antirheumatic AgentsMESH: Decision TreesMESH: Treatment FailureArthritisMESH: Antibodies Anti-IdiotypicMESH: Logistic ModelsLogistic regressionSeverity of Illness IndexArthritis Rheumatoid0302 clinical medicineimmune system diseasesImmunology and AllergyMESH: Data CollectionPharmacology (medical)Treatment Failure030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesMESH: Arthritis RheumatoidData CollectionAntibodies Anti-Idiotypic3. Good healthMESH: Interleukin 1 Receptor Antagonist ProteinMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemAntirheumatic AgentsRheumatoid arthritismedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorImmunologyPeptides Cyclic03 medical and health sciencesRheumatologyRheumatoid FactorMESH: Severity of Illness IndexInternal medicineSeverity of illnessmedicineHumansRheumatoid factorMESH: Physician's Practice PatternsMESH: Peptides Cyclic030203 arthritis & rheumatologyAnakinraMESH: HumansTumor Necrosis Factor-alphabusiness.industryDecision Treesmedicine.diseaseRheumatologyInterleukin 1 Receptor Antagonist ProteinLogistic ModelsMethotrexateMESH: Tumor Necrosis Factor-alphaPhysical therapyMethotrexatebusinessArthritis & Rheumatism
researchProduct

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic mod…

Male0301 basic medicineDimethyl FumarateNeurodegenerativemultiple sclerosis; coronavirus; pneumoniaSeverity of Illness Indexlaw.inventionImmunosuppressive AgentImmunologic Factor0302 clinical medicineNatalizumablawMonoclonalMultiple Sclerosi80 and overLungHumanizedResearch ArticlesAged 80 and overNatalizumabMiddle AgedIntensive care unitHospitalizationSettore MED/26 - NEUROLOGIAIntensive Care UnitsNeurologyMethylprednisoloneNeurologicalPneumonia & InfluenzaInterferonFemaleImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMusc-19 Study GroupMultiple SclerosisAdolescentClinical SciencesIntensive Care UnitClinical NeurologySettore MED/26Antibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesYoung Adult03 medical and health sciencesClinical ResearchInternal medicineSeverity of illnessmedicineHumansImmunologic FactorsMortalityAdolescent; Adult; Aged; Aged 80 and over; Antibodies Monoclonal Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young AdultAgedNeurology & NeurosurgeryExpanded Disability Status ScaleFingolimod HydrochlorideSARS-CoV-2business.industryMultiple sclerosisNeurosciencesCOVID-19PneumoniaOdds ratiomedicine.diseaseBrain DisordersGood Health and Well Being030104 developmental biologyOcrelizumabInterferonsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct